Careers

Careers

Passionate to help us save lives?

Our product range

Our development pipeline

Phase 1

Phase 2

Phase 3

Approval

Launch

IgG Next Generation (BT595) - Primary Immune Deficiency (PID)
IgG Next Generation (BT595) - Idiopathic Thrombocytopenic Purpura (ITP)
Fibrinogen (BT524) - Congenital fibrinogen deficiency
Fibrinogen (BT524) - Acquired fibrinogen deficiency
Trimodulin (BT588) - Severe community acquired pneumonia
Trimodulin (BT588) - "Severe" COVID-19
Haemophilia A Therapeutic (HAT) - Haemophilia A

Pipeline

Pipeline

Press releases

Biotest's sustainability campaign GoFuture part of the ...

24.06.2024,

24.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Milestone for Biotest: US approval for innovative immun...

17.06.2024,

17.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest increased sales by 83.6% to Euro 215.2 million ...

07.05.2024,

07.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Annual General Meeting approves dividend distribution

07.05.2024,

07.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest AG opens 12th plasma collection centre in Germa...

19.04.2024,

19.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest AG increased sales by 32% in the financial year...

28.03.2024,

28.03.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest achieves EBIT forecast for 2023

29.02.2024,

29.02.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Karl Lauterbach visits Biotest AG's plasma donation cen...

28.02.2024,

28.02.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest successfully meets primary endpoint in phase II...

14.02.2024,

14.02.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Preliminary announcement of the publication of financia...

30.01.2024,

30.01.2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ... ... [More]

Preliminary announcement of the publication of financia...

22.01.2024,

22.01.2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ... ... [More]

Biotest AG opens 11th plasma collection centre in Germa...

18.01.2024,

18.01.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Preliminary announcement of the publication of financia...

11.01.2024,

11.01.2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at ... ... [More]

Biotest expands its clinical development program for tr...

12.12.2023,

12.12.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest’s Trimodulin shows reduced mortality in patient...

28.11.2023,

28.11.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest increases EBIT to Euro 125.4 million in the fir...

02.11.2023,

02.11.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Peter Janssen appointed new Chairman of the Board of Bi...

05.10.2023,

Announcement according to Article 17 European Market Abuse Regulation (MAR)  Peter Janssen appointed new Chairman of the Board of Biotest AG Dreieich, 5 October 2023. In its m ... [More]

Increase of the EBIT guidance

05.10.2023,

Announcement according to Article 17 European Market Abuse Regulation (MAR)  Increase of the EBIT guidance Dreieich, 05 October 2023. Against the background of the agreements ... [More]

Biotest receives approval for innovative immunoglobulin...

21.09.2023,

21.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Biotest treats first patient with severe community-acqu...

12.09.2023,

12.09.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Se ... [More]

Investor Relations

Investor Relations

The primary objective of our Investor Relations activities is an open and up-to-date dialogue with the financial community.

Renate & Hans Schleussner Award

Renate & Hans Schleussner Award

Third Renate & Hans Schleussner Research Award 2023/2024 on Hyper-Immunoglobulins now online.

War in Ukraine